지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.4
- 수록면
- 355 - 364 (10page)
- DOI
- 10.14366/usg.21167
이용수
이 논문의 연구 히스토리 (2)
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Purpose: This study aimed to assess the inter-platform reproducibility of ultrasound attenuation examination in patients with nonalcoholic fatty liver disease (NAFLD).Methods: Between March 2021 and April 2021, patients with clinically suspected or known NAFLD were prospectively enrolled; each patient underwent ultrasound attenuation examinations with three different platforms (Attenuation Imaging [ATI], Canon Medical System; Tissue Attenuation Imaging [TAI], Samsung Medison; and Ultrasound-Guided Attenuation Parameter [UGAP], GE Healthcare) on the same day. The mean attenuation coefficient (AC) values of the three platforms were compared using repeated-measures analysis of variance with the Bonferroni correction. To evaluate inter-platform reproducibility, the AC values obtained for each platform were compared using Bland-Altman analysis with the calculation of 95% limits of agreement (LOA), intraclass correlation coefficients (ICCs), and coefficients of variation (CVs).Results: Forty-six patients (23 men; mean age±standard deviation, 52.3±12.4 years) were enrolled. The mean AC values showed significant differences among the three platforms (0.75±0.12, 0.80±0.11, and 0.74±0.09 dB/cm/MHz for ATI, TAI, and UGAP, respectively; P<0.001). For inter-platform reproducibility, the 95% LOAs were -0.22 to 0.11 dB/cm/MHz between ATI and TAI, -0.17 to 0.18 dB/cm/MHz between ATI and UGAP, and -0.08 to 0.20 dB/cm/MHz between TAI and UGAP, respectively. The pairwise ICCs were 0.790-0.797 in terms of absolute agreement among the three platforms; the CVs were 8.23%-9.47%.Conclusion: The AC values obtained from different ultrasound attenuation examination platforms showed significant differences, with significant inter-platform variability. Therefore, the AC values measured using different ultrasound attenuation examination techniques should not be used interchangeably for longitudinal follow-up of patients with NAFLD.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease
Journal of Obesity & Metabolic Syndrome
2020 .01
-
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
-
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Clinical and Molecular Hepatology
2023 .02
-
The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease
Gut and Liver
2024 .07
-
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Clinical and Molecular Hepatology
2023 .04
-
비알코올성지방간의 유관 인자 임상 연구: 종양표지자, 심박변이도, 사상체질
JSCM : Journal of Sasang constitutional medicine
2019 .01
-
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Clinical and Molecular Hepatology
2023 .02
-
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2022 .07
-
Implications of comorbidities in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
-
Personalized medicine in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2022 .10
-
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Clinical and Molecular Hepatology
2023 .04
-
The growing burden of non-alcoholic fatty liver disease on mortality
Clinical and Molecular Hepatology
2023 .04
-
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations
Clinical and Molecular Hepatology
2022 .10
-
Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
Clinical and Molecular Hepatology
2021 .01
-
Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study
Clinical Hypertension
2015 .01
-
비알코올 지방간질환에 대한 한의학 연구 동향 보고: 국내 논문을 중심으로
대한한방내과학회지
2022 .09
-
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2021 .01
-
Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
Diabetes and Metabolism Journal
2023 .03
-
Nonalcoholic Fatty Liver Disease Is a Stepping Stone in the Path toward Diabetes Mellitus
Gut and Liver
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0